Olema Pharmaceuticals, Inc. ( NASDAQ:OLMA – Get Free Report ) has earned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eleven have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $40.60.
A number of research firms have recently weighed in on OLMA. HC Wainwright dropped their target price on Olema Pharmaceuticals from $38.00 to $36.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th. JPMorgan Chase & Co. decreased their price target on Olema Pharmaceuticals from $52.00 to $46.00 and set an “overweight” rating for the company in a report on Thursday, August 13th. Citigroup lowered their price target on Olema Pharmaceuticals to $59.00 and set a “buy” rating for the company in a research report on Tuesday, August 11th. Weiss Ratings upgraded Olema Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday. Finally, Wall Street Zen c...